business
World-first cancer vaccine succeeds in lab, disappoints on market
Australian scientists say a world-first personalized cancer vaccine has succeeded in late-stage global trials, reducing the risk of melanoma returning or causing death by 42 percent. The results were due to be presented at a healthcare conference in Madrid on Sunday, but an oncology news website published key data early on Friday, breaking the embargo. Professor Georgina Long, the Australian researcher overseeing the development, called the outcome a milestone in cancer treatment. The vaccine is tailored to each patient to help the immune system target their specific tumor. Despite the clinical success, the report notes the breakthrough has disappointed on the market, signaling investor expectations had run ahead of the data. Researchers say the next step is completing the formal presentation and moving toward broader regulatory review.
Latest updates
World-first cancer vaccine succeeds in lab, disappoints on market
Australian scientists say a world-first personalized cancer vaccine has succeeded in late-stage global trials, reducing the risk of melanoma returning or causing death by 42 percent. The results were due to be presented at a healthcare conference in Madrid on Sunday, but an oncology news website published key data early on Friday, breaking the embargo. Professor Georgina Long, the Australian researcher overseeing the development, called the outcome a milestone in cancer treatment. The vaccine is tailored to each patient to help the immune system target their specific tumor. Despite the clinical success, the report notes the breakthrough has disappointed on the market, signaling investor expectations had run ahead of the data. Researchers say the next step is completing the formal presentation and moving toward broader regulatory review.